{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-277478","form_type":"8-K","ticker":"RVTY","cik":"0000031791","company_name":"REVVITY, INC.","filed_at":"2021-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.326987+00:00","generated_at":"2026-06-29T02:26:33.895413+00:00","sec_items":["2.01","1.01","2.03","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"PerkinElmer closes $5.25B BioLegend acquisition; issues ~14.1M shares as stock consideration","bullets":["Aggregate purchase price ~$5.25B; paid 59.5% cash and 40.5% stock valued at $156.3561/share.","Cash funded by $2.28B notes offering, $500M term loan draw, ~$300M revolver draw, and cash on hand.","Transaction closed on September 17, 2021; previously announced on July 25, 2021.","Issued 14,066,771 shares of common stock in a private placement to BioLegend stockholders.","Financial statements and pro forma information to be filed by amendment within 71 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-277478","json":"https://secwatch.observer/filing/0001193125-21-277478.json","markdown":"https://secwatch.observer/filing/0001193125-21-277478.md","text":"https://secwatch.observer/filing/0001193125-21-277478.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/31791/000119312521277478/0001193125-21-277478-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/31791/000119312521277478/d233653d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:26:33.895413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}